Ultragenyx Pharmaceutical (NASDAQ:RARE) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) in a report released on Tuesday,Benzinga reports. The firm currently has a $60.00 target price on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued reports about the company. Jefferies Financial Group reduced their price objective on Ultragenyx Pharmaceutical from $114.00 to $63.00 and set a “buy” rating for the company in a report on Tuesday, December 30th. Robert W. Baird dropped their price target on Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating for the company in a research report on Tuesday, December 30th. Barclays cut their price target on Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating for the company in a research note on Monday, November 24th. Truist Financial lowered their price objective on shares of Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Finally, Guggenheim dropped their target price on shares of Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a report on Monday, January 5th. Sixteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $72.29.

Ultragenyx Pharmaceutical Stock Up 0.2%

NASDAQ:RARE opened at $24.80 on Tuesday. Ultragenyx Pharmaceutical has a fifty-two week low of $18.41 and a fifty-two week high of $46.50. The stock has a market cap of $2.39 billion, a PE ratio of -4.18 and a beta of 0.16. The firm’s fifty day simple moving average is $28.70 and its 200-day simple moving average is $29.97.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.58). The company had revenue of $159.93 million during the quarter, compared to analyst estimates of $167.42 million. Ultragenyx Pharmaceutical had a negative net margin of 91.95% and a negative return on equity of 414.17%. The firm’s revenue for the quarter was up 14.6% on a year-over-year basis. During the same quarter last year, the business earned ($1.40) EPS. Equities analysts anticipate that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Howard Horn sold 3,061 shares of the business’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $23.56, for a total value of $72,117.16. Following the completion of the transaction, the chief financial officer owned 88,935 shares of the company’s stock, valued at approximately $2,095,308.60. The trade was a 3.33% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last three months, insiders sold 6,227 shares of company stock worth $187,126. Company insiders own 5.50% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Institutional investors have recently modified their holdings of the company. Assetmark Inc. grew its stake in Ultragenyx Pharmaceutical by 1,706.7% in the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,024 shares during the period. Huntington National Bank boosted its holdings in shares of Ultragenyx Pharmaceutical by 56.2% during the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 393 shares during the last quarter. Danske Bank A S purchased a new stake in shares of Ultragenyx Pharmaceutical in the third quarter valued at $39,000. Smartleaf Asset Management LLC grew its position in shares of Ultragenyx Pharmaceutical by 205.4% in the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 1,169 shares during the period. Finally, Covestor Ltd increased its stake in Ultragenyx Pharmaceutical by 26.0% in the third quarter. Covestor Ltd now owns 1,787 shares of the biopharmaceutical company’s stock valued at $54,000 after purchasing an additional 369 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.